Clinical trials: Eye
Ametropia
Performance of Aspheric Hydrogel Lenses After a Refit With Sphere Silicone Hydrogel Lenses for 4 Weeks
The aim of this prospective study is to evaluate the clinical performance of habitual wearers of methafilcon A aspheric lenses after a refit with fanfilcon A sphere lenses for 4 weeks of daily wear.
- Trial name
- NCT03835078
- Testing
- methafilcon A contact lenses, fanfilcon A contact lenses
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- CooperVision, Inc.
Inflammation Associated With Cataract Surgery
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
- Trial name
- NCT01606735
- Testing
- IBI-10090
- Where
- 2 sites in United States
- Volunteers
- 172 people
- Sponsor
- ICON Bioscience Inc
Myopia, Hyperopia
A Clinical Comparison of Two Soft Contact Lenses
The study objective was to gather short-term clinical performance data for two soft contact lenses.
- Trial name
- NCT05741450
- Testing
- Lens 1 (monthly replacement), Lens 2 (daily disposable)
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- CooperVision, Inc.
Posterior Blepharitis
Topical IL-1-Ra for Treatment of Posterior Blepharitis
The purpose of this study is to determine the effectiveness and safety of Topical Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior blepharitis.
- Trial name
- NCT00681109
- Testing
- 2.5% IL-1Ra, 5% IL-1Ra
- Volunteers
- 75 people
- Sponsor
- Reza Dana, MD
Presbyopia
Comparison of Two Multifocal Contact Lenses
The purpose of this study is to compare two multifocal contact lenses in presbyopic wearers.
- Trial name
- NCT01250054
- Testing
- Lotrafilcon B contact lens, Comfilcon A contact lens
- Volunteers
- 17 people
- Sponsor
- CIBA VISION
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Idiopathic Intracranial Hypertension
Surgical Idiopathic Intracranial Hypertension Treatment Trial
Randomized trial of adults (≥18 years old) with idiopathic intracranial hypertension and moderate to severe visual loss without substantial recent treatment who are randomly assigned to (1) medical therapy, (2) medical therapy…
- Trial name
- SIGHT (NCT03501966)
- Testing
- Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting
- Where
- 36 sites in United States, Canada and 1 more
- Volunteers
- 7 people
- Sponsor
- Jaeb Center for Health Research
Rhinoconjunctivitis, Rhinitis
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced…
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00978029
- Testing
- SCH 39641
- Volunteers
- 203 people
- Sponsor
- ALK-Abelló A/S
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- ENDURE (NCT01032915)
- Testing
- AIN457
- Where
- 94 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Myopia
A Contralateral Dispensing Clinical Trial of Study Test Sapphire Lens Against Enfilcon A Silicone Hydrogel Lens
This was be a randomized, contralateral, double-masked, dispensing study comparing the Study test lens against the control lens over one month of lens wear. The study results were not used for design validation of test lens.
- Trial name
- NCT02518490
- Testing
- Sapphire Lens, enfilcon A
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- CooperVision, Inc.
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Dry Eye Disease
Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
- Trial name
- NCT04201574
- Testing
- ALY688 0.1%, ALY688 0.4%, Vehicle
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allysta Pharmaceutical
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Dry Eye
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber
- Trial name
- NCT05102409
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution)
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Myopia
Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period
The purpose of this trial is to compare two different contact lenses during 4 weeks of wear.
- Trial name
- NCT00810511
- Testing
- Lotrafilcon A contact lens, Comfilcon A contact lens
- Volunteers
- 213 people
- Sponsor
- CIBA VISION
Scleral Buckling
The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble
A controlled clinical study comparing the effect of topical aqueous suppressants on intraocular gas duration.
- Trial name
- NCT01843920
- Testing
- Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Jason Hsu, MD
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD).
- Trial name
- PULSAR (NCT04423718)
- Testing
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Where
- 235 sites in United States, Argentina and 25 more
- Volunteers
- 1,011 people
- Sponsor
- Bayer
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.